Ursodeoxycholic acid and its unexpected application areas
https://doi.org/10.21518/2079-701X-2020-5-77-85
Abstract
Introduction. Ursodeoxycholic acid (UDCA) came into modern medicine in the 1970s as a potential solvent for small gallstones. But as early as the 1980s, there were clinical studies to improve biochemical indices when using UDCA in other liver diseases. These studies initiated a worldwide active study of the clinical possibilities and various therapeutic effects of UDCA in various diseases, including those beyond the liver. Today, worldwide, UDCA drugs are the lifelong basis for the treatment of primary sclerosing cholangitis (PSC). It is indicated for all types of hepatitis: infectious, toxic, drug-induced, autoimmune and others. It can be stated that the history of study and introduction of UDCA drugs in medicine is the history of the expansion of its application areas, which continues to this day. The purpose of the review is to present the results of the use of UDCA drugs outside the traditional circle of cholestatic liver diseases, the causes and possibilities of their use in other areas of medicine.
Main principles. It has been shown that UDCA, originally designed for the treatment of cholestatic liver diseases, along with the known antioxidant, antifibrotic and immunomodulatory effects has a proven fundamental apoptosis regulatory effect. This allows it to have as a possible therapeutic target a whole range of extrahepatic diseases, such as gastrointestinal lesions (IBD, clostridi-osis, radiation and medical intestinal lesions, etc.), diseases of the cardiovascular system, neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, ALS), prion diseases (Kuru, Creutzfeldt-Jakob disease) and a number of others.
Conclusion. According to modern views, UDCA can be considered as a unique drug of universal cytoprotective action, the expansion of its therapeutic possibilities is promising and is subject to further multilateral study.
About the Author
A. R. Reyzis
Central Research Institute of Epidemiology
Russian Federation
Russian Federation
Ara R. Reyzis - Dr. of Sci. (Med.), Professor, Lead Researcher, CLinicaL Department.
34 Novogireevskaya St., Moscow, 111123
References
1. AbdeLkader N.F., Safar M.M., Salem H.A. Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations. Mol Neurobiol. 2016;53(2):810-817. doi: 10.1007/s12035-014-9043-8.
2. Pang L., Zhao X., Liu W., Zhang W., Yang M., Li G.L. et al. Anticancer Effect of Ursodeoxycholic Acid in Human Oral Squamous Carcinoma HSl-3 Cells through the Caspases. Nutrients. 2015;7(5):3200—3218. doi: 10.3390/nu7053200.
3. Vang S., Longley K., Steer CJ., Low W.C. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob AdvHealth Med. 2014;3(3):58-69. doi: 10.7453/gahmj.2014.017.
4. Barrasa J.I., Olmo N., Lisarbe M. A., Turnay J. Bile acids in the colon from healthy to cytotoxic molecules15. Bile acids in the colon, from healthy to cytotoxic olecules. Toxicol in Vitro. 2013;27(2):964-977. doi: 10.1016/j.tiv.2012.12.020.
5. Yu H., Fu O.R., Huang ZJ., Lin J.Y., Chen O.X., Wang O., Shen D.Y. Apoptosis induced by ursodeoxycholic acid in human melanoma cells through the mitochondrial pathway. Oncol Rep. 2019;41(1):213-223. doi: 10.3892/or.2018.6828.
6. Reyzis A.R., Matanina N.V., SHmarov D.A. Apoptosis of peripheral blood lymphocytes in hepatitis A, B, C in children. Actual issues of infectious pathology in children. Moscow; 2004, pp. 199-200.
7. Reyzis A.R., Matanina N.V., Shmarov D.A. Apoptosis of peripheral white blood cells in the pathogenesis of viral hepatites and the antiapoptotic effect of ursodeoxycholic acid. Infektsionnye bolezni = Infectious Deseases. 2006;4(2):5-9. (In Russ.) Available at: http://www.phdynasty.ru/katalog/zhurnaly/infektsionnye-bolezni/2006/tom-4-nomer-2/11655.
8. Reizis A.R., Matanina N.V., Shmarov D.A. The apoptosis of peripheral blood mononuclear cells during viral hepatitis in children and its correction by ursodeoxycholic acid. Journal of Hepatology. 2006;44(suppl.2):p.116. doi: 10.1016/S0168-8278(06)80298-9.
9. Reyzis A.R., Matanina N.V. Correction of pathogenetic disorders is an important direction in the treatment of viral hepatitis. Gepatologiya = Hepatology. 2005;(3):31-33. (In Russ.) Available at: http://www.fesmu.ru/elib/Article.aspx?id=135359.
10. Reyzis A.R., Matanina N.V., SHmarov D.A. Apoptosis and antiapoptotic therapy in chronic hepatitis B and C, G. Detskie infektsii = Children infections. 2006;5(4):11-14. (In Russ.) Available at: https://cyberleninka.ru/article/n/ apoptoz-i-antiapoptoticheskaya-terapiya-pri-hronicheskih-gepatitah-v-i-s/viewer.
11. Matanina N.V., Reizis A.R. Peripheral blood lymphocyte apoptosis in children with viral hepatitis A, B, C and effect of ursodeoxycholic acid preparations. Exp Clin Gastroenterol. 2008;(5):106-110. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19145924.
12. Reizis A.R., Borzakova S.N. Apoptosis in the pathogenesis of viral and drug-induced liver damages and the ways of its normalization. Ehpidemiologiya i infektsionnye bolezni. Aktual’nye voprosy = Epidemiology and Infectious Diseases. Current Items. 2011;(1):1-4. (In Russ.) Available at: https://epidemiology-journal.ru/ru/archive/article/11361.
13. Meng F., Kennedy L., Hargrove L., Demieville I., lones H., Madeka T. et al. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2-/- mice and human primary sclerosing cholangitis. Lab Invest. 2018;98(11):1465-1477. doi: 10.1038/s41374-018-0101-0.
14. Tang N., Zhang Y., Liang O., Liu Z., Shi Y The role of ursodeoxycholic acid on cholestatic hepatic fibrosis in infant rats. Mol Med Rep. 2018;17(3):3837-3844. doi: 10.3892/mmr.2017.8284.
15. Ye H.L., Zhang J.W., Chen X.Z., Wu P.B., Chen L., Zhang G. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autopha-gy. Life Sci. 2020;242:117175. doi: 10.1016/j.lfs.2019.117175.
16. Reyzis A.R., KHokhlova O.N., Drondina A.K. New aspects of autoimmune hepatitis: early recognition and alternative treatment. Doktor.Ru = Doctor Ru. 2011;2(61):57-63. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=17330050.
17. Reyzis A.R., KHokhlova O.N., Drondina A.K. New aspects of autoimmune hepatitis. Meditsinskiy al’manakh = Medical almanac. 2012;(20):78-79. (In Russ.) Available at: http://www.fesmu.ru/elib/Article.aspx?id=255433.
18. Ruutu T., Juvonen E., Remberger M., Remes K., Volin L., Mattsson J. et al.; the Nordic Group for Blood and Marrow Transplantation. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant. 2014;20(1):135-138. doi: 10.1016/j.bbmt.2013.10.014.
19. Vang S., Longley K., Steer CJ., Low W.C. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Global Advances in Health and Medicine. 2014;3(3):58-69. doi: 10.7453/gahmj.2014.017.
20. Perugorria M.G., Labiano J., Esparza-Baquer M., Marzioni M. et al. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. Dig Dis. 2017;35(3):275-281. doi: 10.1159/000450989.
21. DAgnolo H.M., Kievit W., Takkenberg R.B. et al. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. J Hepatol. 2016;65(3):601-607. doi: 10.1016/j.jhep.2016.05.009.
22. Yijima T., Hochino J., Suwabe T., Sumida K., Mise K., Kawada M. et al. Ursodeoxycholic Acid for Treatment of enlarged Polycystic liver. Ther Apher Dial. 2016;20(1):73-78. doi: 10.1111/1744-9987.12326.
23. Munoz-Garrido P., Marin JJ., Perugoria M., Urribarri A.D., Erice O., Saez E. et al. Ursodeoxycholic acid inhibits Hepatic cystogenesis in experimental models of Polycystic liver disease. J Hepatolog. 2015;63(4):952-961. doi: 10.1016/j.jhep.2015.05.023.
24. Abdallah E., Emile S.H., Elfeki H., Fikry M., Abdelshafy M., Elshobaky A. et al. Role of ursodeoxycholic acid in the prevention of gallstone formation after laparoscopic sleeve gastrectomy. Surg Today 2017;47(7):844-850. doi: 10.1007/s00595-016-1446-x.
25. Talha A., Abdelbaki T., Farouk A., Hasouna E., Azzam E., Shehata G. Cholelithiasis after bariatric surgery, incidence, and prophylaxis: randomized controlled trial. Surg Endosc. 2019. doi: 10.1007/s00464-019-07323-7.
26. Thibault M., McMahon J., Faubert G., Charbonneau J., Malo J., Ferreira E., Mohamed I. Parenteral nutrition-associated liver disease: a retrospective study of ursodeoxycholic Acid use in neonates. J Pediatr Pharmacol Ther. 2014;19(1):42-48. doi: 10.5863/1551-6776-19.1.42.
27. Simić D., Milojević I., Bogićević D., Milenović M., Radlović V., Drasković B. et al. Preventive effect of ursodeoxycholic acid on parenteral nutrition-associated liver disease in infants. Srp Arh Celok Lek. 2014;142(3-4):184-188. doi: 10.2298/sarh1404184s.
28. Dubreuil M., Ruiz-Gaspa S., Guanabens N., Peris P., Alvarez L., Monegal A. et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver Int. 2013;33(7):1029-1038. doi: 10.1111/liv.12153.
29. Kelly O.B., Mroz M.S., Ward J.B., Colliva C., Scharl M., Pellicciari R. et al. Ursodeoxycholic acid attenuates colonic epithelial secretory function. J Physiol. 2013;591(pt9):2307-2318. doi: 10.1113/jphysiol.2013.252544.
30. Golden J.M., Escobar O.H., Nguyen M.V., Mallicote M.U., Kavarian P.. Frey M.R., Gayer C.P. Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G259-G271. doi: 10.1152/ajpgi.00354.2017.
31. Webb BJ., Brunner A., Lewis J., Ford C.D., Lopansri B.K. Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent Recurrent Clostridioides difficile Infection. Clin Infect Dis. 2019;68(3):498-500. doi: 10.1093/cid/ciy568.
32. Weingarden A.R., Chen C., Zhang N., Graiziger C.T., Dosa P.I., Steer CJ. et al. Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection. Clin Gastroenterol. 2016;50(8):624-630. doi: 10.1097/MCG.0000000000000427.
33. Kim S.H., Ch HJ., Choi H.S., Kime S., Keum B., Seo Y.S. et al. Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model. Oncol Lett. 2018;16(2):2585-2590. doi: 10.3892/ol.2018.8893.
34. Reyzis A.R. Ursodeoxycholic acid and cancer prevention. Meditsinskiy sovet = Medical Council. 2019;(14):39-43. (In Russ.) doi: 10.21518/2079-701X-2019-14-39-43.
35. Mohamed A.S., Hanafi N.I., Sheikh Abdul Kadir S.H., Md Noor J., Abdul Hamid Hasani N., Ab Rahim S., Siran R. Ursodeoxycholic acid protects car-diomyocytes against cobalt chloride induced hypoxia by regulating transcriptional mediator of cells stress hypoxia inducible factor 1a and p53 protein. Cell Biochem Funct. 2017;35(7):453-463. doi: 10.1002/cbf.3303.
36. von Haehling S.. Schefold J.C., Jankowska E.A., Springer J., Vazir A.. Kalra P.R. et al. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 2012;59(6):585-592. doi: 10.1016/j.jacc.2011.10.880.
37. Hanafi NJ., Mohamed A.S., Sheikh Abdul Kadir S.H., Othman M.H.D. Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart. Biomolecules. 2018;8(4):59. doi: 10.3390/biom8040159.
38. Bell S.M., Barnes K., Clemmens H., Al-Rafiah A.R., Al-Ofi E.A., Leech V. et al. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease. J Mol Biol. 2018;430(21):3942-3953. doi: 10.1016/j.jmb.2018.08.019.
39. Ko W.K., Kim SJ., Jo MJ., Choi H., Lee D., Kwon I.K. et aL. UrsodeoxychoLic Acid Inhibits Inflammatory Responses and Promotes Functional Recovery After Spinal Cord Injury in Rats. Mol Neurobiol.2019;56(1):267-277. doi: 10.1007/s12035-018-0994-z.
40. Mortiboys H., Furmston R., Bronstad G., AasLy J., ELLiott C., Bandmann O. UDCA exerts beneficiaL effect on mitochondriaL in LRRK2 (G2019S) carriers and in vivo. Neurology. 2015;85(10):846-852. doi: 10.1212/WNL.0000000000001905.
41. Cortez L.M., Campeau J., Norman G., KaLayiL M., Van der Merwe J., McKenzie D., Sim V.L. BiLe Acids Reduce Prion Conversion, Reduce NeuronaL Loss, and ProLong MaLe SurvivaL in ModeLs of Prion Disease. J Virol. 2015;89(15):7660-7672. doi: 10.1128/JVI.01165-15.
42. Daruich A., Picard E., Boatright J.H., Behar-Cohen F. Review: The biLe acids urso- and tauroursodeoxychoLic acid as neuroprotective therapies in retinaL disease. Mol Vis. 2019;25:610-624. AvaiLabLe at: https://www.ncbi.nLm.nih.gov/pubmed/31700226.
43. Shima K.R., Ota T., Kato K.I., Takeshita Y., Misu H., Kaneko S., Takamura T. UrsodeoxychoLic acid potentiates dipeptidyL peptidase-4 inhibitor sitag-Liptin by enhancing gLucagon-Like peptide-1 secretion in patients with type 2 diabetes and chronic Liver disease: a piLot randomized controLLed and add-on study. BMJ Open Diabetes Res Care. 2018;6(1):e000469. doi: 10.1136/bmjdrc-2017-000469.
44. Sanches-Garsia A., Sahebcar A., SimentaL-Mendia M., SimentaL-Mendia L.E. Effect of ursodeoxychoLic acid on gLycemic markers: A systematic review and meta-anaLysis of cLinicaL triaLs. Pharmacol Res. 2018;135:144-149. doi: 10.1016/j.phrs.2018.08.008.
Review
For citations:
Reyzis AR. Ursodeoxycholic acid and its unexpected application areas. Meditsinskiy sovet = Medical Council. 2020;(5):77-85. (In Russ.) https://doi.org/10.21518/2079-701X-2020-5-77-85
Views:
1512
Email this article 